Hologic's (HOLX) New Offering to Revitalize Cynosure Division

Leading player in the field of women's health, Hologic, Inc. HOLX recently announced that its Cynosure division has launched the FDA-approved TempSure Surgical RF technology in North America. Notably, this latest product belonging to the TempSure radiofrequency (RF) platform allows surgical and non-surgical aesthetic procedures across several specialties on a single device.

Following the FDA's inquiry on products used in energy-based women's health procedures, Cynosure has decided to continue marketing its MonaLisa Touch CO2 laser. The company has also returned TempSure Vitalia hand pieces and probes to the market. These developments are expected to boost the top-line contribution from Cynosure division in the near term.

Market Potential

According to MarketsandMarkets, the global medical aesthetics market is expected to reach a worth of $13.29 billion, at a CAGR of 10.8% from 2016 to 2021. Thus, the company clearly has bountiful opportunities in this niche market, both globally and internationally.

A Glimpse of the Cynosure Business

Hologic has been seeing declining Cynosure sales as a result of the FDA's letter regarding certain women's health procedures and the company's voluntary decision to suspend marketing of its TempSure Vitalia product. Notably, sales in the fiscal fourth quarter were more than $15 million lower than expected due to refunds and rebates related to previous sales of Vitalia handpieces, unused probes, and TempSure systems along with decreased MonaLisa Touch sales.

We believe the latest progress will help the company overcome these obstacles and deliver solid performance.

Share Price Movement

Hologic has consistently outperformed its industry over the past six months. The stock has gained 6% versus 5.5% decline of the industry.

Zacks Rank & Key Picks

Hologic currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader medical space are Veeva Systems VEEV , Integer Holdings Corporation ITGR and Surmodics, Inc. SRDX .

Veeva Systems' long-term earnings growth rate is estimated at 19.5%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Integer Holdings has an expected earnings growth rate of 30.3% for 2018 and a Zacks Rank #1.

Surmodics' long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 (Buy).

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Veeva Systems Inc. (VEEV): Free Stock Analysis Report

Hologic, Inc. (HOLX): Free Stock Analysis Report

Integer Holdings Corporation (ITGR): Free Stock Analysis Report

Surmodics, Inc. (SRDX): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More